-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an accessory disease of peripheral nerves and nerve roots.
is characterized by a gradual increase in symmetrical movement, loss of sensation, and weakness associated with loss of deep tendon reflexes.
CIDP is caused by damage to a nerve overlay called myelin, a gradual onset of CIDP can delay diagnosis for months or even years, leading to severe nerve damage that may limit and delay the response to treatment.
most patients need long-term treatment, and if left untreated, nearly one-third of CIDP patients will develop wheelchair-dependent.
early identification and appropriate treatment are essential to avoid disability.
Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved PANZYGA®'s Application for a Supplemental Biologics License (sBLA) to allow it to treat CIDP adult patients.
PANZYGA can be given up to 12 mg / kg / min infusion speed.
Lukin, global president of Pfizer's hospital business unit, said: "Every CIDP patient has different treatment needs, and we find that having an approved dose option is not always the best choice.
approval of this new adaptation will enable healthcare providers to select approved doses that are appropriate for patients, which will help meet the needs of unseeded patients."
